Cold Spring Harbor Laboratory

3 weeks ago | cshl.edu | Samuel Diamond

The Takeaway CSHL Professor David Tuveson and Research Investigator Claudia Tonelli have found a way to “intercept” pancreatic cancer. By inhibiting the cancer gene FGFR2, they were able to slow tumor formation. By targeting the FGFR2 and EGFR proteins, they were able to prevent pancreatic cancer from forming in the first place. Your browser does not support the audio element.

3 weeks ago | cshl.edu | Samuel Diamond

As the world’s population ages, neurodegenerative conditions like Alzheimer’s disease are becoming more and more common. Alzheimer’s is the leading cause of dementia. And though research into these conditions has yielded many fascinating results, few have translated to clinical applications. Today, we have a better idea of what Alzheimer’s does to the brain. However, we’re still a long way from figuring out how to cure the disease or prevent it from taking hold in the first place.

1 month ago | cshl.edu | Samuel Diamond

For science to positively impact the world, it must be shared. It must be circulated among scientists and communicated with the public. Over the past decade, the free online platforms bioRxiv and medRxiv, developed at Cold Spring Harbor Laboratory (CSHL), have revolutionized how biomedical research is shared around the world. Accelerating their success now becomes the mission of openRxiv, a newly launched, community-oriented, independent nonprofit. bioRxiv was founded in 2013, and medRxiv in 2019.

2 months ago | cshl.edu | Samuel Diamond

The Takeaway In a new study, Cold Spring Harbor Laboratory Professor Hiro Furukawa and postdoc Hyunook Kang prove the existence of a mysterious brain receptor known as GluN1-2B-2D. They also show several ways the drug ketamine can interact with GluN1-2B-2D. Their research may lead to safer treatments for depression, anxiety, and other mental health conditions.

2 months ago | cshl.edu | Samuel Diamond

Cold Spring Harbor Laboratory Associate Professor Tobias Janowitz has been elected to the American Society for Clinical Investigation (ASCI). Janowitz is recognized for his outstanding scholarly research, which approaches cancer from a whole-body perspective. He has led clinical trials and published authoritative studies on cancer cachexia, a debilitating condition that affects patients in the late stages of the disease. “I am pleased to become a member of the ASCI,” says Janowitz.